AxoGen, Inc.
AXGN
NASDAQ·Healthcare·Medical - Devices·Mkt cap $2.6B
$48.28
▲ +2.51%
P/E
-71.46
Mkt Cap
$2.6B
52-Wk Range
$15.27–$52.91
52-Week Range
$15.27 - $52.91
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 201.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary processed human nerve allograft technology eliminating need for autografts and secondary surgical sites
- Comprehensive product portfolio addressing multiple aspects of peripheral nerve repair and protection
- Established relationships with key surgical specialties and military hospital networks
- Regulatory clearances and market presence across multiple international markets
Bear Case
2 risks
- Average volatility.
- Extreme premium - high expectations embedded
Growth
Turning profitable
Rising incidence of peripheral nerve injuries from trauma, diabetes, and surgical complications
Value
Extreme premium - high expectations embedded
Momentum
Strong
+16.4% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying AXGN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
JUL 29, 2026
Reported EPS of $0.12 vs $0.12 consensus (-1.1% surprise). Revenue of $69.7M vs $67.1M expected (+3.9%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-1.1%
Revenue trend · last 8Q
—
+15%
+17%
+18%
+24%
+21%
+27%
+23%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$48.6M
$49.4M
$48.6M
$56.7M
$60.1M
$59.9M
$61.5M
$69.7M
Margins · last 8Q
Gross
72.7%
Operating
-3.1%
Profit
-2.2%
Wall Street consensus
7 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Jul 30, 2026
vs Industry
How AXGN stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related